• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

AGI chief joins XP advisory board

Freeport, N.Y. - Daniel B. Yarosh, Ph.D., president and CEOof AGI Dermatics, has been named to the Xeroderma PigmentosumSociety's Scientific Advisory Board.

Freeport, N.Y. - Daniel B. Yarosh, Ph.D., president and CEO of AGI Dermatics, has been named to the Xeroderma Pigmentosum Society's Scientific Advisory Board.

An acclaimed molecular biologist who has devoted 20 years to studying the effects of sun on DNA and skin, Dr. Yarosh is the inventor of Dimericine. This first therapeutic DNA repair enzyme can reduce the incidence of pre-cancers and basal cell carcinoma. Dimericine is currently in clinical testing for Food and Drug Administration approval as a topical prescription drug.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 KOL is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.